Autopsy report · NCT05229601

A Study of HFB301001 in Adult Patients With Advanced Solid Tumors

“The decision to discontinue the trial was made as part of a strategic review of the Sponsor's global development portfolio. It is not related to any safety concerns, efficacy findings, recruitment difficulties, or issues with trial conduct.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 3 months before it started.
• Ran for about 2 years 1 month before it stopped.
• 31 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

HiFiBiO Therapeutics

Sponsor type

Industry

Conditions

Soft Tissue Sarcoma; Renal Cell Carcinoma; Uterine Carcinosarcoma; Hepatocellular Carcinoma; Head and Neck Squamous Cell Carcinoma; Melanoma

Interventions

HFB301001

Participants

31

Sites

10

Countries

Spain, United States

Trials that died the same way

• A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors
  “This trial was terminated voluntarily by the Sponsor for reasons related to its corporate strategic development, with no safety concerns or efficacy signals related to the investigational product identified.” (75% match in meaning)
• Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
  “Sponsor decided to discontinue the study due to strategic considerations and not due to any safety-related concerns.” (75% match in meaning)
• A Study to Investigate Use of Off-the-shelf Natural Killer (NK) Cells (SAR445419) in Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
  “Sponsor decision to cancel trial, not related to safety concern.” (73% match in meaning)
• Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers
  “The study was terminated due to the sponsor's decision to discontinue the clinical trial.” (73% match in meaning)
• A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Low Back Pain
  “Based on lack of efficacy in PAI2003, sponsor made the decision to discontinue the trial.” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.